STL Volume 12 Number 7
Update on Drugs and Drug News – September 2007
Update on Adapalene Differin® Gel 0.3%, Adalimumab HUMIRA®, Hyaluronic Acid Injectable Soft Tissue Filler Cangene ELEVESS®, Ketoconazole Extina® Foam 2%.
TNF-a Inhibitors in Dermatology
To date, the US FDA has approved three tumor necrosis factor (TNF)-a inhibitors for use in dermatology. The distinct and targeted mechanism of action of the TNF inhibitors allows dermatologists to customize therapy to match the individual needs and characteristics of patients who are candidates for systemic therapy.
New Developments in Hormonal Therapy for Acne
Oral contraceptives (OCs) are a valuable option for the treatment of women with acne. The use of OCs can be considered across the spectrum of acne disease severity in women. In Canada, three preparations are approved for mild-to-moderate acne, and a fourth is indicated for severe acne.
